{"id":"W2529895151","doi":"10.1182/blood.v118.21.269.269","title":"Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Rituximab; Medicine; Obinutuzumab; Internal medicine; Follicular lymphoma; Clinical endpoint; Regimen; Population; CD20; Neutropenia; Phases of clinical research; Clinical trial; Oncology; Lymphoma; Surgery; Gastroenterology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002183812,0.001315571,0.00264236,0.0003128696,0.000280098,0.000888686,0.000948887,0.001374207,0.004348796],"category_scores_gemma":[0.001662991,0.0005495517,0.001630033,0.000315185,0.001071438,0.0008949951,0.0005321963,0.002064485,0.00102457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008093077,"about_ca_system_score_gemma":0.00136224,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00082599,"about_ca_topic_score_gemma":0.001833323,"domain_scores_codex":[0.9991738,0.0005754291,0.000032896,0.0000888253,0.00003614363,0.00009291985],"domain_scores_gemma":[0.9987634,0.0004156593,0.0002232772,0.0001121264,0.00006321218,0.0004222781],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.983759,0.004963963,0.001412299,0.0001443855,0.0005876851,0.00004191103,0.0000420979,0.0003157153,0.001976736,0.00006086497,0.0002918531,0.00640345],"study_design_scores_gemma":[0.8951531,0.1015759,0.00194653,0.00001131505,0.0003739695,0.00002259385,0.00001802249,0.0002932642,0.0001831742,0.00006981112,0.0003442633,0.000007864168],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942098,0.001130079,0.0003370557,0.0004150589,0.0001341293,0.002263375,0.0004864223,0.00006601385,0.000958153],"genre_scores_gemma":[0.9900758,0.001005509,0.001355988,0.00098059,0.0002610127,0.00306948,0.001511907,0.00002052977,0.001719332],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004348796,"threshold_uncertainty_score":0.01454812,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02219480741726867,"score_gpt":0.2705518785369483,"score_spread":0.2483570711196797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}